Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inmune Bio, Inc.INMB · Entity 7094 | Director | September 15, 2026 | September 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inmune Bio, Inc.
Report date September 15, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2036-09-14 | Direct | 100,000 |
Reported balance
After 2026-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 100,000 · Balance 100,000 F1: Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 23, 2026 10:05 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001213900-26-102342 · ownership.xml · derivative · entry 1 Clark Ronnie Duane · CIK 0002155825 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-09-14 F1 · derivative.exercise_date: Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.